Narcolepsy and cataplexy

Handbook of Clinical Neurology

Volumn 99, Issue C, 2011, Pages 783-814

  Nishino, Seiji ^a,b   Mignot, Emmanuel ^a  

^a STANFORD UNIVERSITY   (United States)

^b Circadian Neurobiology Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR2 ANTIGEN; NEUROPEPTIDE; OREXINS; SIGNAL PEPTIDE;

ANIMAL; CULTURAL FACTOR; DIFFERENTIAL DIAGNOSIS; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; NARCOLEPSY; REVIEW;

ANIMALS; CROSS-CULTURAL COMPARISON; DIAGNOSIS, DIFFERENTIAL; DISEASE MODELS, ANIMAL; HLA-DR2 ANTIGEN; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NARCOLEPSY; NEUROPEPTIDES;

EID: 78149376377     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52007-4.00007-2     Document Type: Book

References (255)

1. Alaila S.L. Life effects of narcolepsy: measures of negative impact, social support and psychological well-being. Loss, Grief and Care: Psychosocial Aspects of Narcolepsy 1992, 1-22. Haworth Press, New York. M. Goswanmi, C.P. Pollak, F.L. Cohen (Eds.).
2. Aldrich M. The clinical spectrum of narcolepsy and idiopathic hypersomnia. Neurology 1996, 46:393-401.
3. Aldrich M.S. Automobile accidents in patients with sleep disorders. Sleep 1989, 12:487-494.
4. Aldrich M.S. The neurobiology of narcolepsy-cataplexy. Prog Neurobiol 1993, 41:533-541.
5. Aldrich M.S., Naylor M.W. Narcolepsy associated with lesions of the diencephalon. Neurology 1989, 39:1505-1508.
6. Aldrich M.S., Prokopowicz G., Ockert K., et al. Neurochemical studies of human narcolepsy: alpha-adrenergic receptor autoradiography of human narcoleptic brain and brainstem. Sleep 1994, 17:598-608.
7. Aldrich M.S., Chervin R.D., Malow B.A. Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy. Sleep 1997, 20:620-629.
8. American Academy of Sleep Medicine ICSD-2 - International Classification of Sleep Disorders. Diagnostic and Coding Manual 2005, AASM, Westchester, Illinois. 2nd edn.
9. American Narcolepsy Association Stimulant medication survey. The Eye Opener 1992, 1-3.
10. Anic-Labat S., Guilleminault C., Kraemer H., et al. Validation of a cataplexy questionnaire in 983 sleep disorder patients. Sleep 1999, 22:77-87.
11. Arii J., Kanbayashi T., Tanabe Y., et al. A hypersomnolent girl with decreased CSF hypocretin level after removal of a hypothalamic tumor. Neurology 2001, 56:1775-1776.
12. Arii J., Kanbayashi T., Tanabe Y., et al. CSF hypocretin-1 (orexin-A) levels in childhood narcolepsy and neurologic disorders. Neurology 2004, 63:2440-2442.
13. Aston-Jones G., Chen S., Zhu Y., et al. A neural circuit for circadian regulation of arousal. Nat Neurosci 2001, 4:732-738.
14. Babcock D.A., Narver E.L., Dement W.C., et al. Effects of imipramine, chlorimipramine, and fluoxetine on cataplexy in dogs. Pharmacol Biochem Behav 1976, 5:599-602.
15. Baker T.L., Dement W.C. Canine narcolepsy-cataplexy syndrome: evidence for an inherited monoaminergic-cholinergic imbalance. Brain Mechanisms of Sleep 1985, 199-233. Raven Press, New York. D.J. McGinty, R. Drucker-Colin, A. Morrison (Eds.).
16. Baker T.L., Foutz A.S., McNerney V., et al. Canine model of narcolepsy: genetic and developmental determinants. Exp Neurol 1982, 75:729-742.
17. Baraitser M., Parkes J.D. Genetic study of narcoleptic syndrome. J Med Genet 1978, 15:254-259.
18. Bassetti C., Aldrich M.S. Idiopathic hypersomnia. A series of 42 patients. Brain 1997, 120:1423-1435.
19. Billiard M. Kleine Levin syndrome. Principles and Practice of Sleep Medicine 1989, 377-378. WB Saunders, Philadelphia. M.H. Krieger, T.T. Roth, W.C. Dement (Eds.).
20. Billiard M., Seignalet J. Extraordinary association between HLA-DR2 and narcolepsy. Lancet 1985, 1:226-227.
21. Billiard M., Besset A., Cadilhac J. The clinical and polygraphic development of narcolepsy. Sleep/Wake Disorders: Natural History, Epidemiology and Longterm Evolution 1983, 171-185. Raven Press, New York. C. Guilleminault, E. Lugaresi (Eds.).
22. Billiard M., Salva M.Q., DeKoninck J., et al. Daytime sleep characterisitcs and their relationships with night sleep in the narcoleptic patient. Sleep 1986, 9:167-174.
23. Billiard M., Laaberki M.F., Reygrobellet C., et al. Elevated antibodies to streptococcal antigens in narcoleptic subjects. Sleep Res 1989, 18:201.
24. Billiard M., Pasquie-Magnetto V., Heckman M., et al. Family studies in narcolepsy. Sleep 1994, 17:S-54-S-59.
25. Bishop C., Rosenthal L., Helmus T., et al. The frequency of multiple sleep onset REM periods among subjects with no excessive daytime sleepiness. Sleep 1996, 19:727-730.
26. Black J.E., Brooks S.N., Nishino S. Narcolepsy and syndromes of primary excessive daytime somnolence. Semin Neurol 2004, 24:271-282.
27. Black J.L., Krahn L.E., Pankratz V.S., et al. Search for neuron-specific and nonneuron-specific antibodies in narcoleptic patients with and without HLA DQB1*0602. Sleep 2002, 25:719-723.
28. Black J.L., Avula R.K., Walker D.L., et al. HLA DQB1*0602 positive narcoleptic subjects with cataplexy have CSF IgG reactive to rat hypothalamic protein extract. Sleep 2005, 28:1191-1192.
29. Black J.L., Silber M.H., Krahn L.E., et al. Studies of humoral immunity to preprohypocretin in human leukocyte antigen DQB1*0602-positive narcoleptic subjects with cataplexy. Biol Psychiatry 2005, 58:504-509.
30. Bowersox S., Kilduff T., Faul K., et al. Brain dopamine receptor levels elevated in canine narcolepsy. Brain Res 1987, 402:44-48.
31. Broughton R., Ghanem Q. The impact of compound narcolepsy on the life of the patient. Narcolepsy 1976, 201-220. Spectrum, New York. C. Guilleminault, W.C. Dement, P. Passouant (Eds.).
32. Broughton R., Ghanem Q., Hishikawa Y., et al. Life effects of narcolepsy in 180 patients from North America, Asia and Europe compared to matched controls. Can J Neurol Sci 1981, 8:299-303.
33. Broughton R., Valley V., Aguirre M., et al. Excessive daytime sleepiness and pathophysiology of narcolepsy-cataplexy: a laboratory perspective. Sleep 1986, 9:205-215.
34. Broughton R., Duschene P., Aguirre M., et al. A single nap is as accurate as the MSLT in diagnosing EDS in narcolepsy-cataplexy. Sleep Res 1988, 17:150.
35. Broughton R., Dunham W., Newman J., et al. Ambulatory 24 hour sleep-wake monitoring in narcolepsy-cataplexy compared to matched control. Electroencephalogr Clin Neurophysiol 1988, 70:473-481.
36. Guilleminault C. Narcolepsy and its differential diagnosis. Sleep and its Disorders in Children 1987, 181-194. Raven Press, New York. C. Guilleminault (Ed.).
37. Guilleminault C. Narcolepsy syndrome. Principles and Practice of Sleep Medicine 1994, 549-561. W. B. Saunders, Philadelphia. 2nd edn. M.H. Kryger, T. Roth, W.C. Dement (Eds.).
38. Guilleminault C., Wilson R.A., Dement W.C. A study on cataplexy. Arch Neurol 1974, 31:255-261.
39. Narcolepsy 1976, Spectrum, New York. C. Guilleminault, W.C. Dement, P. Passouant (Eds.).
40. Guilleminault C., Mignot E., Grumet F.C. Familial patterns of narcolepsy. Lancet 1989, 2:1376-1379.
41. Carskadon M.A., Dement W.C., Mitler M.M., et al. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep 1986, 9:519-524.
42. Castelli M.P., Ferraro L., Mocci I., et al. Selective gamma-hydroxybutyric acid receptor ligands increase extracellular glutamate in the hippocampus, but fail to activate G protein and to produce the sedative/hypnotic effect of gamma-hydroxybutyric acid. J Neurochem 2003, 87:722-732.
43. Challamel M.J., Mazzola M.E., Nevsimalova S., et al. Narcolepsy in children. Sleep 1994, 17:S17-S20.
44. Chemelli R.M., Willie J.T., Sinton C.M., et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999, 98:437-451.
45. Chervin R.D., Kraemer H.C., Guilleminalt C. Correlates of sleep latency on the multiple sleep latency test in a clinical population. Electroencephalogr Clin Neurophysiol 1995, 95:147-153.
46. Chetrit M., Besset A., Damci D., et al. Hypnogogic hallucinations associated with sleep onset REM period in narcolepsy-cataplexy. J Sleep Res 1994, 3:43.
47. Chokroverty S. Sleep apnea in narcolepsy. Sleep 1986, 9:250-253.
48. Cohen F.L., Smith K.M. Learning and memory in narcoleptic patients and controls. Sleep Res 1989, 18:117.
49. Dahlitz M., Parkes J.D. Sleep paralysis. Lancet 1993, 341:406-407.
50. Dalal M.A., Schuld A., Haack M., et al. Normal plasma levels of orexin A (hypocretin-1) in narcoleptic patients. Neurology 2001, 56:1749-1751.
51. Daniels L.E. Narcolepsy. Medicine 1934, 13:1-122.
52. Dauvilliers Y., Neidhart E., Lecendreux M., et al. MAO-A and COMT polymorphisms and gene effects in narcolepsy. Mol Psychiatry 2001, 6:367-372.
53. Dauvilliers Y., Montplaisir J., Molinari N., et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 2001, 57:2029-2033.
54. Dauvilliers Y., Billiard M., Montplaisir J. Clinical aspects and pathophysiology of narcolepsy. Clin Neurophysiol 2003, 114:2000-2017.
55. Dauvilliers Y., Baumann C.R., Carlander B., et al. CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry 2003, 74:1667-1673.
56. Dauvilliers Y., Carlander B., Rivier F., et al. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 2004, 56:905-908.
57. Dauvilliers Y., Maret S., Bassetti C., et al. A monozygotic twin pair discordant for narcolepsy and CSF hypocretin-1. Neurology 2004, 62:2137-2138.
58. Dauvilliers Y., Blouin J.L., Neidhart E., et al. A narcolepsy susceptibility locus maps to a 5Mb region of chromosome 21q. Ann Neurol 2004, 56:382-388.
59. De Lecea L., Kilduff T.S., Peyron C., et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998, 95:322-327.
60. Dement W., Rechtschaffen A., Gulevich G. The nature of the narcoleptic sleep attack. Neurology 1966, 16:18-33.
61. Dement W.C. Daytime sleepiness and sleep " attacks" Narcolepsy 1976, 17-42. Spectrum, New York. C. Guilleminault, W.C. Dement, P. Passouant (Eds.).
62. Dement W.C., Carskadon M., Ley R. The prevalence of narcolepsy II. Sleep Res 1973, 2:147.
63. Dohi K., Ripley B., Fujiki N., et al. CSF hypocretin-1/orexin-A concentrations in patients with subarachnoid hemorrhage (SAH). Peptides 2005, 26:2339-2343.
64. Eriksson K.S., Sergeeva O., Brown R.E., et al. Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J Neurosci 2001, 21:9273-9279.
65. Evarts E.V. Temporal patterns of discharge of pyramidal tract neurons during sleep and waking in the monkey. J Neurophysiol 1964, 27:152-171.
66. Evarts E.V. Relation of discharge frequency to conduction velocity in pyramidal tract neurons. J Neurophysiol 1965, 28:216-228.
67. Faull K.F., Guilleminault C., Berger P.S., et al. Cerebrospinal fluid monoamine metabolites in narcolepsy and hypersomnia. Ann Neurol 1983, 13:258-263.
68. Frederickson S., Carlander B., Billiard M., et al. CSF immune variable in patients with narcolepsy. Acta Neurol Scand 1990, 81:253-254.
69. Fukuda K., Miyasita A., Inugami M., et al. High prevalence of isolated sleep paralysis: Kanashibari phenomenon in Japan. Sleep 1987, 10:279-286.
70. Fujiki N., Nishino S. Hypocretin/orexin replacement therapy in hypocretin/orexin deficient narcolepsy: an overview. The Orexin/Hypocretin System: Physiology and Pathophysiology 2006, 367-388. Humana Press, Totowa. S. Nishino, T. Sakurai (Eds.).
71. Fujiki N., Yoshida Y., Ripley B., et al. Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation. Neuroreport 2001, 12:993-997.
72. Fujiki N., Morris L., Mignot E., et al. Analysis of onset location, laterality and propagation of cataplexy in canine narcolepsy. Psychiatry Clin Neurosci 2002, 56:275-276.
73. Fujiki N., Ripley B., Yoshida Y., et al. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin ligand deficient narcoleptic dog. Sleep 2003, 6:953-959.
74. Fujiki N., Yoshino F., Lovenberg T.W., et al. Wake promoting effects of non-imidazolin histamine H3 antagonist in orexin/ataxin-3 narcoleptic mice. Sleep 2006, 29:A230.
75. Gelb M., Guilleminault C., Kraemer H., et al. Stability of cataplexy over several months -information for the design of therapeutic trials. Sleep 1994, 17:265-273.
76. Genton P., Benlakhel K., Disdier P., et al. Diagnosis of narcolepsy-cataplexy: importance of continuous recording in ambulatory EEG. Report of 20 cases. Neurophysiol Clin 1995, 25:187-195.
77. Godbout R., Montplaisir J. Comparison of sleep parameters in narcoleptics with and without periodic movements of sleep. Sleep '84 1985, 380-382. Fischer, Gustav. W.P. Koella, E. Ruther, H. Schulz (Eds.).
78. Goode B. Sleep paralysis. Arch Neurol 1962, 6:228-234.
79. Hagan J.J., Leslie R.A., Patel S., et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci U S A 1999, 96:10911-10916.
80. Hara J., Beuckmann C.T., Nambu T., et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001, 30:345-354.
81. Hecht M., Lin L., Kushida C.A., et al. Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy. Sleep 2003, 26:809-810.
82. Hendricks J.C., Morrison A.R., Mann G.L. Different behaviors during paradoxical sleep without atonia depend on pontine lesion site. Brain Res 1982, 239:81-105.
83. Henneberg R. Uber genuine narkolepsie. Neurologisches Zentralblatt 1916, 30:282-290.
84. Hishikawa Y. Sleep paralysis. Narcolepsy 1976, 97-124. Spectrum, New York. C. Guilleminault, W.C. Dement, P. Passpouant (Eds.).
85. Hishikawa Y., Shimizu T. Physiology of REM sleep, cataplexy, and sleep paralysis. Negative Motor Phenomena 1995, 245-271. Lippincott-Raven, Philadelphia. S. Fahn, M. Hallet, H.O. Lüders (Eds.).
86. Hishikawa Y., Wakamatsu H., Furuya E., et al. Sleep satiation in narcoleptic patients. Electroencephalogr Clin Neurophysiol 1976, 41:1-18.
87. Hohjoh H., Terada N., Nakayama T., et al. Case-control study with narcoleptic patients and healthy controls who, like the patients, possess both HLA-DRB1*1501 and -DQB1*0602. Tissue Antigens 2001, 57:230-235.
88. Honda Y. Census of narcolepsy, cataplexy and sleep life among teen-agers in Fujisawa city. Sleep Res 1979, 8:191.
89. Honda Y. Clinical features of narcolepsy. HLA in Narcolepsy 1988, 24-57. Springer, Berlin. Y. Honda, T. Juji (Eds.).
90. Honda Y., Matsuki K. Genetic aspects of narcolepsy. Handbook of Sleep Disorder 1990, 217-234. Marcel Dekker, New York. M. Thorpy (Ed.).
91. Honda Y., Asaka A., Tanimura M., et al. A genetic study of narcolepsy and excessive daytime sleepiness in 308 families with a narcolepsy or hypersomnia proband. Sleep/Wake Disorders: Natural History, Epidemiology and Long Term Evolution 1983, 198-229. Raven Press, New York. C. Guilleminault, E. Lugaresi (Eds.).
92. Honda Y., Doi Y., Ninomiya R., et al. Increased frequency of non-insulin-dependent diabetes mellitus among narcoleptic patients. Sleep 1986, 9:254-259.
93. Horvath T.L., Peyron C., Diano S., et al. Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. J Comp Neurol 1999, 415:145-159.
94. Huang Z.L., Qu W.M., Li W.D., et al. Arousal effect of orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci U S A 2001, 98:9965-9970.
95. Hublin C., Partinen M., Kaprio J., et al. Epidemiology of narcolepsy. Sleep 1994, 17:S7-S12.
96. Hublin C., Kaprio J., Partinene M., et al. The prevalence of narcolepsy: an epidemiological study of the Finnish twin cohort. Ann Neurol 1994, 35:709-716.
97. Hungs M., Fan J., Lin L., et al. Identification and functional analysis of mutations in the hypocretin (orexin) genes of narcoleptic canines. Genome Res 2001, 11:531-539.
98. Jimbo M., Takahaski Y., Suzuki J. Polygraphic studies of nocturnal sleep of narcoleptics II. The effects of some psychotropic drugs on the appearance of paradoxical phases and hypnagogic hallucinations 1963, 182.
99. Juji T., Satake M., Honda Y., et al. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. Tissue Antigens 1984, 24:316-319.
100. Kaitin K.I., Kilduff T.S., Dement W.C. Evidence for excessive sleepiness in canine narcoleptics. Electroencephalogr Clin Neurophysiol 1986, 64:447-454.
101. Kales A., Soldates C.R., Bixler E.O. Narcolepsy-cataplexy II: Psychosocial consequences and associated psychopathology. Arch Neurol 1982, 39:169-171.
102. Kanbayashi T., Honda K., Kodama T., et al. Implication of dopaminergic mechanisms in the wake-promoting effects of amphetamine: a study of d- and l-derivatives in canine narcolepsy. Neuroscience 2000, 99:651-659.
103. Kanbayashi T., Inoue Y., Chiba S., et al. CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J Sleep Res 2002, 11:91-93.
104. Kessler S., Guilleminault C., Dement W.C. A family study of 50 REM narcoleptics. Acta Neurol Scand 1979, 50:503-512.
105. 11C-raclopride. Neurology 1994, 44:2102-2104.
106. Kilduff T., Bowersox S.S., Kaitin K.I., et al. Muscarinic cholinergic receptors and the canine model of narcolepsy. Sleep 1986, 9:102-107.
107. Kimura K., Tachibana N., Kohyama J., et al. A discrete pontine ischemic lesion could cause REM sleep behavior disorder. Neurology 2000, 55:894-895.
108. 1R) in the regulation of sleep. Sleep 2000, 23:A91.
109. Kish S., Mamelak M., Slimovitch C., et al. Brain neurotransmitter changes in human narcolepsy. Neurology 1992, 42:229-234.
110. Knecht C.D., Oliver J.E., Redding R., et al. Narcolepsy in a dog and a cat. J Am Vet Med Assoc 1973, 162:1052-1053.
111. Krabbe E., Magnussen G. Familial narcolepsy. Acta Psychiatr Scand 1942, 17:149-173.
112. Krahn L.E., Pankratz V.S., Oliver L., et al. Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status. Sleep 2002, 25:733-736.
113. Kubota H., Kanbayashi T., Tanabe Y., et al. Decreased cerebrospinal fluid hypocretin-1 levels near the onset of narcolepsy in 2 prepubertal children. Sleep 2003, 26:555-557.
114. Kushida C.A., Baker T.L., Dement W.C. Electroencephalographic correlates of cataplectic attacks in narcoleptic canines. Electroencephalogr Clin Neurophysiol 1985, 61:61-70.
115. Kuwata S., Tokunaga K., Jin F., et al. Letter to the editor after Dr Aldrich's review on narcolepsy. N Engl J Med 1991, 324:270-272.
116. Lammers G.J., Van Dijk J.G. The Multiple Sleep Latency Test: a paradoxical test?. Clin Neurol Neurosurg 1992, 94:S108-S110.
117. Lammers G.J., Arends J., Declerck A.C., et al. Gamma-hydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep 1993, 16:216-220.
118. Lammers G.J., Pijl H., Iestra J., et al. Spontaneous food choice in narcolepsy. Sleep 1996, 19:75-76.
119. Langdon N., Welsh K.I., Van Dam M., et al. Genetic markers in narcolepsy. Lancet 1984, 2:1178-1180.
120. Lankford D.A., Wellman J.J., O'Hara C. Posttraumatic narcolepsy in mild to moderate closed head injury. Sleep 1994, 17:S25-S28.
121. Lavie P., Peled R. Narcolepsy is a rare disease in Israel. Sleep 1987, 10:608-609.
122. Lecendreux M., Maret S., Bassetti C., et al. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res 2003, 12:347-348.
123. Lee M.G., Hassani O.K., Jones B.E. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci 2005, 25:6716-6720.
124. Lin L., Faraco J., Li R., et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999, 98:365-376.
125. Löwenfeld L. Uber Narkolepsie. Munch Med Wochenschr 1902, 49:1041-1045.
126. MacFarlane J.G., List S.J., Moldovsly H., et al. Dopamine D2 receptors quantified in vivo in human narcolepsy. Biol Psychiatry 1997, 41:305-310.
127. Maitre M. The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol 1997, 51:337-361.
128. Malik S., Boeve B.F., Krahn L.E., et al. Narcolepsy associated with other central nervous system disorders. Neurology 2001, 57:539-541.
129. Mamelak M., Black J., Montplaisir J., et al. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 2004, 27:1327-1334.
130. Matsuki K., Juji T., Honda Y. Immunological features of narcolepsy in Japan. HLA in Narcolepsy 1988, 150-157. Springer, New York. Y. Honda, T. Juji (Eds.).
131. Matsuki K., Grumet F.C., Lin X., et al. DQ rather than DR gene marks susceptibility to narcolepsy. Lancet 1992, 339:1052.
132. Mayer G., Pollmächer T., Meier-Ewert K., et al. [Assessment of the degree of disability in narcolepsy.]. Gesundheitswesen 1993, 55:337-342.
133. Mayer G., Hellmann F., Leonhard E., et al. Circadian temperature and activity rhythms in unmedicated narcoleptic patients. Pharmacol Biochem Behav 1997, 58:395-402.
134. Mefford I.N., Baker T.L., Boehme R., et al. Narcolepsy: biogenic amine deficits in an animal model. Science 1983, 220:629-632.
135. Melberg A., Ripley B., Lin L., et al. Hypocretin deficiency in familial symptomatic narcolepsy. Ann Neurol 2001, 49:136-137.
136. Mieda M., Willie J.T., Hara J., et al. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A 2004, 101:4649-4654.
137. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998, 50:S16-S22.
138. Mignot E. Perspectives in narcolepsy and hypocretin (orexin) research. Sleep Med 2000, 1:87-90.
139. Mignot E., Nishino S. Emerging therapies in narcolepsy-cataplexy. Sleep 2005, 28:754-763.
140. Mignot E., Guilleminault C., Grumet F.C., et al. Is narcolepsy an autoimmune disease?. Proceedings of the Third Milano International Symposium, September 18-19 " Sleep, Hormones, and the Immune System" 1992, 29-38. Masson, Milan. S. Smirne, M. Francesci, L. Ferini-Strambi (Eds.).
141. Mignot E., Renaud A., Nishino S., et al. Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology 1993, 113:76-82.
142. Mignot E., Nishino S., Sharp L.H., et al. Heterozygosity at the canarc-1 locus can confer susceptibility for narcolepsy: induction of cataplexy in heterozygous asymptomatic dogs after administration of a combination of drugs acting on monoaminergic and cholinergic systems. J Neurosci 1993, 13:1057-1064.
143. Mignot E., Nishino S., Guilleminault C., et al. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994, 17:436-437.
144. Mignot E., Lin X., Arrigoni J., et al. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in caucasian and black americans. Sleep 1994, 17:S60-S67.
145. Mignot E., Meehan J., Grumet F.C., et al. HLA studies in sporadic and familial narcolepsy. 13th Congress of the European Sleep Research Society 1996, Brussels, Belgium.
146. Mignot E., Hayduk R., Black J., et al. HLA Class II studies in 509 narcoleptic patients. Sleep Res 1997, 26:433.
147. Mignot E., Kimura A., Lattermann A., et al. Extensive HLA class II studies in 58 non DRB1*15 (DR2) narcoleptic patients with cataplexy. Tissue Antigens 1997, 49:329-341.
148. Mignot E., Young T., Lin L., et al. Reduction of REM sleep latency associated with HLA-DQB1*0602 in normal adults. Lancet 1998, 351:727.
149. Mignot E., Lin L., Rogers W., et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 2001, 68:686-699.
150. Mignot E., Lammers G.J., Ripley B., et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002, 59:1553-1562.
151. Mignot E., Chen W., Black J. On the value of measuring CSF hypocretin-1 in diagnosing narcolepsy. Sleep 2003, 26:646-649.
152. Mignot E., Lin L., Finn L., et al. Correlates of sleep-onset REM periods during the Multiple Sleep Latency Test in community adults. Brain 2006, 129:1609-1623.
153. Mileykovskiy B.Y., Kiyashchenko L.I., Siegel J.M. Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron 2005, 46:787-798.
154. Miller J.D., Farber J., Gatz P., et al. Activity of mesencephalic dopamine and non-dopamine neurons across stages of sleep and waking in the rat. Brain Res 1983, 273:133-141.
155. Miller J.D., Faull K.F., Bowersox S.S., et al. CNS monoamines and their metabolites in canine narcolepsy: a replication study. Brain Res 1990, 509:169-171.
156. Mitler M.M. Evaluation of treatment efficacy in narcolepsy. Sleep 1994, 17:S103-S106.
157. Mitler M.M., Boysen B.G., Campbell L., et al. Narcolepsy-cataplexy in a female dog. Exp Neurol 1974, 45:332-340.
158. Mitler M.M., Gujavarty K.S., Browman C.P. Maintenance of wakefulness test: a polysomnographic technique for evaluating treatment in patients with excessive somnolence. Electroenchephalogr Clin Neurophysiol 1982, 53:658-661.
159. Mitler M.M., Walsleben J., Sangal R.B., et al. Sleep latency on the maintenance of wakefulness test (MWT) for 530 patients with narcolepsy while free of psychoactive drugs. Electroencephalogr Clin Neurophysiol 1998, 107:33-38.
160. Montplaisir J., Billard M., Takahashi S., et al. Twenty-four-hour recording in REM-narcoleptics with special reference to nocturnal sleep disruption. Biol Psychiatry 1978, 13:78-89.
161. Montplaisir J., Poirier G., Lapierre O., et al. Streptococcal antibodies in narcolepsy and idiopathic hypersomnia. Sleep Res 1989, 18:271.
162. Moscovitch A., Partinen M., Guilleminault C. The positive diagnosis of narcolepsy and narcolepsy's borderland. Neurology 1993, 43:55-60.
163. Mosko S.S., Shampain D.S., Sassin J.F. Nocturnal REM latency and sleep disturbance in narcolepsy. Sleep 1984, 7:115-125.
164. Mullington J., Broughton R. Scheduled naps in the management of daytime sleepiness in narcolepsy-cataplexy. Sleep 1993, 16:444-456.
165. Nakayama J., Miura M., Honda M., et al. Linkage of human narcolepsy with HLA association to chromosome 4p13-q21. Genomics 2000, 65:84-86.
166. Nambu T., Sakurai T., Mizukami K., et al. Distribution of orexin neurons in the adult rat brain. Brain Res 1999, 827:243-260.
167. Nevsimalova-Bruhova S., Roth B. Heredofamilial aspects of narcolepsy and hypersomnia. Schweiz Arch Neurol Neurochir Psychiatr 1972, 110:45-54.
168. Nishino S. Hypocretin measures in the CSF, and blood and brain tissue. The Orexin/Hypocretin System: Physiology and Pathophysiology 2006, 73-82. Humana Press, Totowa. S. Nishino, T. Sakurai (Eds.).
169. Nishino S., Knbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev 2005, 9:269-310.
170. Nishino S., Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997, 52:27-78.
171. Nishino S., Arrigoni J., Valtier D., et al. Dopamine D2 mechanisms in canine narcolepsy. J Neurosci 1991, 11:2666-2671.
172. Nishino S., Arrigoni J., Shelton J., et al. Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Sleep 1993, 16:706-712.
173. Nishino S., Tafti M., Reid M.S., et al. Muscle atonia is triggered by cholinergic stimulation of the basal forebrain: implication for the pathophysiology of canine narcolepsy. J Neurosci 1995, 15:4806-4814.
174. Nishino S., Honda K., Reid M., et al. Acetylcholine release and neuronal activity in the basal forebrain of freely-moving narcoleptic Dobermans. Sleep Res 1997, 26:444.
175. Nishino S., Mao J., Sampathkumaran R., et al. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online 1998, 1:49-61.
176. Nishino S., Okura M., Mignot E. Narcolepsy: genetic predisposition and neuropharmacological mechanisms. Sleep Med Rev 2000, 4:57-99.
177. Nishino S., Ripley B., Overeem S., et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000, 355:39-40.
178. Nishino S., Riehl J., Hong J., et al. Is narcolepsy REM sleep disorder? Analysis of sleep abnormalities in narcoleptic Dobermans. Neurosci Res 2000, 38:437-446.
179. Nishino S., Fujiki N., Ripley B., et al. Decreased brain histamine contents in hypocretin/orexin receptor-2 mutated narcoleptic dogs. Neurosci Lett 2001, 313:125-128.
180. Nishino S., Ripley B., Overeem S., et al. Low CSF hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001, 50:381-388.
181. Nishino S., Sakurai E., Nevisimalova S., et al. CSF histamine content is decreased in hypocretin-deficient human narcolepsy. Sleep 2002, 25(Suppl):A476.
182. Ohayon M.M., Priest R.G., Caulet M., et al. Hypnagogic and hypnopompic hallucinations: pathological phenomena?. Br J Psychiatry 1996, 169:459-467.
183. Ohayon M.M., Priest R.G., Zulley J., et al. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology 2002, 58:1826-1833.
184. Okun M.L., Lin L., Pelin Z., et al. Clinical aspects of narcolepsy-cataplexy across ethnic groups. Sleep 2002, 25:27-35.
185. Okura M., Riehl J., Mignot E., et al. Sulpiride, a D2/D3 blocker, reduces cataplexy but not REM sleep in canine narcolepsy. Neuropsychopharmacology 2000, 23:528-538.
186. Olafsdottir B.R., Rye D.B., Scammell T.E., et al. Polymorphisms in hypocretin/orexin pathway genes and narcolepsy. Neurology 2001, 57:1896-1899.
187. Ondzé B., Lubin S., Lavandier B., et al. Frequency of narcolepsy in the population of a French departement. Sleep 1999, 22:S121.
188. Orellana C., Villemin E., Tafti M., et al. Life events in the year preceding the onset of narcolepsy. Sleep 1994, 17:S50-S53.
189. Overeem S., Mignot E., van Dijk J.G., et al. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 2001, 18:78-105.
190. Overeem S., Dalmau J., Bataller L., et al. Secondary narcolepsy in patients with paraneoplastic anti-Ma2 antibodies is associated with hypocretin deficiency. J Sleep Res 2001, 11(Suppl 1):166-167.
191. Parkes J.D., Fenton G., Struthers G., et al. Narcolepsy and cataplexy. Clinical features, treatment and cerebrospinal fluid findings. Q J Med 1974, 172:525-536.
192. Parkes J.D., Baraitser M., Marsden C.D., et al. Natural history, symptoms and treatment of the narcoleptic syndrome. Acta Neurol Scand 1975, 52:337-353.
193. Passouant P., Baldy-Moulinier M., Assilloux C. Cataplexy associated with Gélineau's disease; effect of clomipramine.]. Rev Neurol (Paris) 1970, 123:56-60.
194. Pelin Z., Guilleminault C., Rish N., et al. HLA-DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. Tissue Antigens 1998, 1998:96-100.
195. Peyron C., Tighe D.K., van den Pol A.N., et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998, 18:9996-10015.
196. Peyron C., Faraco J., Rogers W., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000, 6:991-997.
197. Plazzi G., Parmeggiani A., Mignot E., et al. Narcolepsy-cataplexy associated with precocious puberty. Neurology 2006, 66:1577-1579.
198. Poirier G., Monplaisir J., Décary F., et al. HLA antigens in narcolepsy and idiopathic central nervous. Sleep 1986, 9:153-158.
199. -/- mice. Br J Pharmacol 2003, 140:315-322.
200. Raynal D. Polygraphic aspects of narcolepsy. Narcolepsy 1976, 669-684. Spectrum, New York. C. Guilleminault, W.C. Dement, P. Passouant (Eds.).
201. Rechtschaffen A., Wolpert E.A., Dement W.C., et al. Nocturnal sleep of narcoleptics. Electroencephalogr Clin Neurophysiol 1963, 15:599-609.
202. Reid M.S., Tafti M., Geary J., et al. Cholinergic mechanisms in canine narcolepsy: I. Modulation of cataplexy via local drug administration into pontine reticular formation. Neuroscience 1994, 59:511-522.
203. Reid M.S., Tafti M., Nishino S., et al. Local administration of dopaminergic drugs into the ventral tegmental area modulate cataplexy in the narcoleptic canine. Brain Res 1996, 733:83-100.
204. Ribstein M. Hypnagogic hallucinations. Narcolepsy 1976, 145-160. Spectrum, New York. C. Guilleminault, W.C. Dement, P. Passouant (Eds.).
205. Richardson G.S., Carskadon M.A., Flagg W., et al. Excessive daytime sleepiness in man: multiple sleep latency measurement in narcoleptic and control subjects. Electroencephalogr Clin Neurophysiol 1978, 45:621-627.
206. Rinne J., Hublin C., Partinen M., et al. PET study of human narcolepsy: no increase in striatal dopamine D2-receptors. Neurology 1995, 45:1735-1738.
207. Ripley B., Fujiki N., Okura M., et al. Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol Dis 2001, 8:525-534.
208. Ripley B., Overeem S., Fujiki N., et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001, 57:2253-2258.
209. Roehrs T., Zorick F., Wittig R., et al. Alerting effects of naps in patients with narcolepsy. Sleep 1986, 9:194-199.
210. Rogers A.E. Problems and coping strategies identified by narcoleptic patients. J Neurosurg Nurs 1984, 16:326-334.
211. Rogers A.E., Rosenberg R.S. Test of memory in narcoleptics. Sleep 1990, 13:42-52.
212. Rosenfeld M.R., Eichen J.G., Wade D.F., et al. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 2001, 50:339-348.
213. Rosenthal C. Uber das aufreten von halluzinatorisch-kataplektischem angstsyndrom, wachanfallen und ahnlichen storungen bei schizophrenen. Mschr Psychiatr Neurol 1939, 102:11-38.
214. Rosenthal L., Merlotti L., Young D., et al. Subjective and polysomnographic characteristics of patients diagnosed with narcolepsy. Gen Hosp Psychiatry 1990, 12:191-197.
215. Roth B. Narcolepsy and Hypersomnia 1980, Karger, Basel.
216. Roth B., Nevsimalova S. Depression in narcolepsy and hypersomnia. Schweiz Arch Neurol Neurochir Psychiatr 1975, 116:291-300.
217. Roth B., Nevsimalova S., Sonka K., et al. An alternative to the multiple sleep latency test to determine sleepiness in narcolepsy and hypersomnia: polygraphic scores of sleepiness. Sleep 1986, 9:243-245.
218. Sachs C., Kaisjer L. Autonomic control of cardiovascular reflexes in narcolepsy. J Neurol Neurosurg Psychiatry 1980, 43:535-539.
219. Sakurai T. Roles of orexin/hypocretin in regulation of sleep/wakefulness and energy homeostasis. Sleep Med Rev 2005, 9:231-241.
220. Sakurai T., Amemiya A., Ishii M., et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998, 92:573-585.
221. Salomon R.M., Ripley B., Kennedy J.S., et al. Diurnal variation of cerebrospinal fluid hypocretin-1 (orexin-A) levels in control and depressed subjects. Biol Psychiatry 2003, 54:96-104.
222. Scammell T.E. The frustrating and mostly fruitless search for an autoimmune cause of narcolepsy. Sleep 2006, 29:601-602.
223. Scammell T.E., Nishino S., Mignot E., et al. Narcolepsy and low CSF orexin (hypocretin) concentration after a diencephalic stroke. Neurology 2001, 56:1751-1753.
224. Schenck C.H., Mahowald M.W. Motor dyscontrol in narcolepsy: rapid-eye-movement (REM) sleep without atonia and REM sleep behavior disorder. Ann Neurol 1992, 32:3-10.
225. Schuld A., Hebebrand J., Geller F., et al. Increased body-mass index in patients with narcolepsy. Lancet 2000, 355:1274-1275.
226. Scrima L., Hartman P.G., Johnson F.H., et al. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures. Biol Psychiatry 1989, 26:331-343.
227. Shelton J., Nishino S., Vaught J., et al. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep 1995, 18:817-826.
228. Shiba T., Fujiki N., Wisor J., et al. Wake promoting effects of thioperamide, a histamine H3 antagonist in orexin/ataxin-3 narcoleptic mice. Sleep 2004, 27(Suppl):A241-A242.
229. Siegel J.M. REM sleep. Principles and Practice of Sleep Medicine 2005, 120-135. Elsevier Saunders, Philadelphia. 4th edn. M.H. Kryger, T. Roth, W.C. Dement (Eds.).
230. Siegel J.M., Nienhuis R., Fahringer H., et al. Neuronal activity in narcolepsy: identification of cataplexy related cells in the medial medulla. Science 1991, 262:1315-1318.
231. Silber M.H., Krahn L.E., Olson E.J., et al. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep 2002, 25:197-202.
232. Smith A.J., Jackson M.W., Neufing P., et al. A functional autoantibody in narcolepsy. Lancet 2004, 364:2122-2124.
233. Smolik P., Roth B. Kleine-Levin syndrome ethiopathogenesis and treatment. Acta Univ Carol Med Monogr 1988, 128:5-94.
234. Solomon P. Narcolepsy in Negroes. Dis Nerv Syst 1945, 6:179-183.
235. Steinfels G.F., Heym J., Streckjer R.E., et al. Behavioral correlates of dopaminergic activity in freely moving cats. Brain Res 1983, 258:217-228.
236. Taheri S., Zeitzer J.M., Mignot E. The role of hypocretins (orexins) in sleep regulation and narcolepsy. Annu Rev Neurosci 2002, 25:283-313.
237. Tashiro T., Kanbayashi T., Hishikawa Y. An epidemiological study of narcolepsy in Japanese. The Fourth International Symposium on Narcolepsy 1994, 13. Tokyo, Japan.
238. Thannickal T.C., Moore R.Y., Nienhuis R., et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000, 27:469-474.
239. Thorpy M.J., Goswami M. Treatment of narcolepsy. Handbook of Sleep Disorders 1990, 235-258. Marcel Dekker, New York. M.J. Thorpy (Ed.).
240. US Modafinil in Narcolepsy Multicenter Study Group Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000, 54:1166-1175.
241. Westphal C. Eigenthümliche mit Einschläfen verbundene Anfälle. Arch Psychiatr Nervenkr 1877, 7:631-635.
242. Wieczorek S., Gencik M., Rujescu D., et al. TNFA promoter polymorphisms and narcolepsy. Tissue Antigens 2003, 61:437-442.
243. Willie J.T., Chemelli R.M., Sinton C.M., et al. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu Rev Neurosci 2001, 24:429-458.
244. Willie J.T., Chemelli R.M., Sinton C.M., et al. Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron 2003, 38:715-730.
245. Wilson S.A.K. The narcolepsies. Annual Congress of the Association of Physicians 1927, 63-109. June 3.
246. Wisor J.P., Nishino S., Sora I., et al. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001, 21:1787-1794.
247. Wu M.F., Gulyani S.A., Yau E., et al. Locus coeruleus neurons: cessation of activity during cataplexy. Neuroscience 1999, 91:1389-1399.
248. Wu M.F., John J., Maidment N., et al. Hypocretin release in normal and narcoleptic dogs after food and sleep deprivation, eating, and movement. Am J Physiol Regul Integr Comp Physiol 2002, 283:R1079-R1086.
249. Wu M.F., John J., Boehmer L.N., et al. Activity of dorsal raphe cells across the sleep-waking cycle and during cataplexy in narcoleptic dogs. J Physiol 2004, 554:202-215.
250. Yamanaka A., Tsujino N., Funahashi H., et al. Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem Biophys Res Commun 2002, 290:1237-1245.
251. Yoshida Y., Fujiki N., Nakajima T., et al. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur J Neurosci 2001, 14:1075-1081.
252. Yoss R.E., Daly D.D. Criteria for the diagnosis of the narcoleptic syndrome. Proc Staff Meet Mayo Clin 1957, 32:320-328.
253. Yoss R.E., Daly D.D. Narcolepsy. Med Clin North Am 1960, 44:953-967.
254. Zeitzer J.M., Buckmaster C.L., Parker K.J., et al. Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness. J Neurosci 2003, 23:3555-3560.
255. Zepelin H., Siegel J.M. Mammalian sleep. Principles and Practice of Sleep Medicine 2005, 91-100. Elsevier Saunders, Philadelphia. 4th edn. M.H. Kryger, T. Roth, W.C. Dement (Eds.).